Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 11/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL29625842 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL429520 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL405854 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL41748 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7141021 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL1377516 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL7137387 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL6052999 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL405855 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL6543502 | 1.00 | SLC6A2 (0.98) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10416175-B2 | Opioid detection | RANDOX LABORATORIES LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-3185015-A1 | OPIOID DETECTION | Randox Laboratories Ltd. (GB) | 2017-06-28 | — | — | EP | disclosed |
| US-20170176476-A1 | Opioid Detection | NORTHERN BANK LIMITED (IE) | 2017-06-22 | — | — | US | disclosed |
| US-20130338166-A1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2114147-B9 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-2486921-A1 | Reducing Side Effects of Tramadol | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2486927-A1 | Treatment of Comorbid Premature Ejaculation and Erectile Dysfunction | DMI Biosciences, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2114147-B1 | REDUCING SIDE EFFECTS OF TRAMADOL | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2120570-B1 | TREATMENT OF COMORBID PREMATURE EJACULATION AND ERECTILE DYSFUNCTION | DMI BIOSCIENCES INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120018333-A1 | Reducing Side Effects of Tramadol | ROSEWIND CORPORATION | 2012-01-26 | — | — | US | disclosed |
| US-20050119349-A1 | Process for chlorinating tertiary alcohols | GRUENENTHAL GMBH (DE) | 2005-06-02 | — | — | US | disclosed |
| EP-1397126-A4 | METHOD OF DELAYING EJACULATION | DMI BIOSCIENCES INC (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1499582-A1 | METHOD FOR CHLORINATING TERTIARY ALCOHOLS | Grünenthal GmbH (DE) | 2005-01-26 | — | — | EP | disclosed |
| EP-1397126-A2 | METHOD OF DELAYING EJACULATION | DMI Biosciences, Inc. (US) | 2004-03-17 | — | — | EP | disclosed |
| EP-1364649-A1 | Adduct of topiramate and tramadol hydrochioride and uses thereof | Cilag AG (CH) | 2003-11-26 | — | — | EP | disclosed |
| WO-2003091199-A1 | METHOD FOR CHLORINATING TERTIARY ALCOHOLS | Grünenthal GmbH (DE) | 2003-11-06 | — | — | WO | disclosed |
| WO-2002074241-A2 | METHOD OF DELAYING EJACULATION | DMI BIOSCIENCES INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-RE37355-E1 | 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients | GRUENENTHAL GMBH (DE) | 2001-09-04 | — | — | US | disclosed |
| US-5733936-A | ANALGESICS | GRUENENTHAL GMBH (DE) | 1998-03-31 | — | — | US | disclosed |
| US-5723668-A | SELECTIVE PRECIPITATION WITH RESOLUTION FROM MOTHER LIQUORS | GRUENENTHAL GMBH (DE) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119349-A1 | Process for chlorinating tertiary alcohols | ADH1C, ADH5, ADH1A | OPRM1 446/4885SLC6A2 3649/4885SLC6A4 2388/4885 |
| US-10416175-B2 | Opioid detection | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885SLC6A2 630/4885SLC6A4 432/4885 |
| US-20170176476-A1 | Opioid Detection | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885SLC6A2 630/4885SLC6A4 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.